Article
Binding of human recombinant mutant soluble ectodomain of FGFR2IIIc to c subtype of FGFRs: implications for anticancer activity.
Oncotarget - 18 Oct 2016
Liu Zhong, Liu Ge, Zhang Guang-Lin, Li Jun, He Yan-Qing, Zhang Shu-Shu, Wang Yi, He Wei-Yi, Cheng Guo-Hua, Yang Xuesong, Xu Jun, Wang Ju
Abstract excerpt
FGFRs are considered essential targets for cancer therapy. We previously reported that msFGFR2c, a Ser252Trp mutant soluble ectodomain of FGFR2IIIc, inhibited tumor growth by blocking FGF signaling pathway. However, the underlying molecular mechanism is still obscure. In this study, we reported that msFGFR2c but not wild-type soluble ectodomain of FGFR2IIIc (wsFGFR2c) could selectively bind to c subtype of FGFRs...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.